WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Sygnature Discovery
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Sygnature Discovery | December 14, 2016
Sygnature Discovery has released a biology publication focusing on our collaboration with Corcept Therapeutics. This work highlights our biomarker validation work and reports the outcome of phase....
Sygnature Discovery | February 01, 2017
Sygnature Discovery, Mironid® Limited, a leader in cell signalling-directed drug discovery and Peak Proteins, have announced they will work closely together to discover new therapies against diseases driven by elevated cyclic AMP (cAMP), such as Autosomal Dominant Polycystic Kidney Disease (ADPKD)....
Sygnature Discovery | March 14, 2017
Keapstone Therapeutics, a new biotech company formed by the University of Sheffield and Parkinson’s UK to develop new drugs for Parkinson’s and other neurodegenerative diseases, and Sygnature Discovery....
Sygnature Discovery | March 29, 2017
One of Sygnature Discovery’s long-term clients, TopiVert Pharma, has recently initiated clinical trials with TOP1288 and TOP1630. Both compounds were first synthesised at Sygnature during the successful collaboration. TOP1288 and TOP1630 are Narrow Spectrum Kinase Inhibitors (NSKIs)....
Pharmacy Market
Whitepaper
Pharma Tech
Video
PHARMACY MARKET
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE